%0 Journal Article
%A Hielscher, Thomas
%A Sill, Martin
%A Sievers, Philipp
%A Stichel, Damian
%A Brandner, Sebastian
%A Jones, David
%A von Deimling, Andreas
%A Sahm, Felix
%A Maas, Sybren L N
%T Clinical implementation of integrated molecular-morphologic risk prediction for meningioma.
%J Brain pathology
%V 33
%N 3
%@ 1015-6305
%C Oxford
%I Wiley-Blackwell
%M DKFZ-2022-02788
%P e13132
%D 2023
%Z #EA:C060#LA:B300# / 2023 May;33(3):e13132
%X Risk prediction for meningioma tumors was until recently almost exclusively based on morphological features of the tumor. To improve risk prediction, multiple models have been established that incorporate morphological and molecular features for an integrated risk prediction score. One such model is the integrated molecular-morphologic meningioma integrated score (IntS), which allocates points to the histological grade, epigenetic methylation family and specific copy-number variations. After publication of the IntS, questions arose in the neuropathological community about the practical and clinical implementation of the IntS, specifically regarding the calling of CNVs, the applicability of the newly available version (v12.5) of the brain tumor classifier and the need for incorporation of TERT-promoter and CDKN2A/B status analysis in the IntS calculation. To investigate and validate these questions additional analyses of the discovery (n = 514), retrospective validation (n = 184) and prospective validation (n = 287) cohorts used for IntS discovery and validation were performed. Our findings suggest that any loss over 5
%K brain tumors (Other)
%K meningioma (Other)
%K molecular biomarkers (Other)
%K risk prediction (Other)
%K tumor classification (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:36377252
%R 10.1111/bpa.13132
%U https://inrepo02.dkfz.de/record/182607